Pacira Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacira Pharmaceuticals, Inc. on August 17, 2015. The filing addresses a specific corporate governance event regarding the appointment of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of James B. Jones, MD, as Senior Vice President and Chief Medical Officer, effective August 17, 2015. Dr. Jones replaces Gary Patou, MD, in this role. Dr. Patou will remain with the company as a clinical consultant.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on strategy, specific risks, contingencies, or unusual items beyond the personnel transition.
Investor Verification Checklist
- Verify the professional background and qualifications of the new Chief Medical Officer, James B. Jones, MD.
- Confirm the terms of the clinical consulting arrangement for the departing CMO, Gary Patou, MD.
- Review subsequent filings for any impact this leadership change may have on clinical trial timelines or regulatory submissions.